Investor Relations

ABK Biomedical Inc. Raises $30M USD in Series B Financing

Halifax, Nova Scotia, April 8th 2019.

ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems. 

ABK Biomedical will use the funding for continued focused product development of its Eye90™ microspheres, which are designed for transarterial radiation therapy for liver tumors, and its Easi-Vue™ microspheres for bland embolic treatment of hypervascular tumors. This Series B raise is intended to support the research and development, manufacturing, and clinical development program designed for regulatory submission of both Eye90™ and Easi-Vue™.

“Our thought-leading physician partners and advisors see tremendous opportunities to improve procedural and oncologic outcomes for patients suffering from non-resectable liver tumors,” said Mike Mangano, president and CEO of ABK Biomedical. “The ABK platform aims to deliver key technical benefits over existing yttrium-90 (Y-90) microspheres technologies for improved procedural and clinical outcomes. ABK combines the benefits of advanced imaging and dosimetry analysis with the empirically proven clinical benefits of Y-90 transarterial radiation therapy.” 

Ketan Patel, MD, partner with F-Prime Capital, comments, “We are impressed with the ABK Biomedical team and believe the company has an outstanding product platform with the potential to make a significant impact on the lives of patients with malignant liver tumors.”

Gregory Sorensen, vice president of strategy and business development with Varian, comments, “ABK has a unique approach to address a large unmet need for patients with non-resectable liver tumors. This technology is aligned with our goal of delivering innovative solutions in cancer care.”

New Strategic Partnership with the University of Missouri Research Reactor Center (MURR®)

Halifax, Nova Scotia, February 13th 2019.

ABK Biomedical Inc. (ABK) is pleased to announce a new multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®).  MURR is the pre-eminent global leader in research reactors, with extensive experience supplying medical isotopes and irradiation services for medical devices.  MURR is a key partner for ABK to establish seamless manufacturing, supply, and distribution to critical cancer centers globally. MURR will be the primary irradiation partner for ABK’s radio-embolization products currently under development.  MURR’s unparalleled reputation for quality control and reliable irradiation services will complement ABK in the research and development of EYE90 microspheres™ for the treatment of liver tumors.

Professor David Robertson discusses MURR, the largest research reactor at any university in the United States at The Society of Nuclear Medicine Annual Meeting in 2019.

ABK Biomedical Inc. Appoints Michael J. Mangano as President and CEO

Halifax, Nova Scotia, July 31st 2018.

ABK Biomedical announced today the appointment of Michael J. Mangano as president and chief executive officer. Mangano will be responsible for leading global business activities, including the rapid development, regulatory approval and commercialization of ABK’s unique medical device technologies.

Mangano most recently served as president and CEO of ReShape Medical, a U.S. venture-backed company focused on obesity where he increased organizational value and played a lead role in orchestrating the sale of the company to EnteroMedics in October 2017. Prior to ReShape, Mangano was president of the Americas for Sirtex Medical, a leading publicly traded Australian biomedical company, where he grew the business nearly five-fold from $30M to more than $140 million while building a team of 17 to more than 130 employees in a period of six years. His leadership resulted in a dramatic increase in the company’s valuation, leading to the recently announced acquisition in progress of Sirtex Medical by CDH Investments for $1.4B USD. Prior to Sirtex, Mangano spent 15 years with Boston Scientific in numerous senior management roles, including overseas assignments in Japan and Australia. Mangano was recently appointed to Board of Directors of Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye diseases.

ABK Biomedical Chairman of the Board Dr. Aaron Berez commented, “Mike is an accomplished leader with a history of global success in building dynamic teams, leading organizational change, creating and shaping strategies and executing programs – all directly increasing shareholder value. His vast experience in sales and marketing management, product development, strategic planning, international business, M&A, project management and business model development will be invaluable as he takes the reins at ABK and leads the company into the next phase of our evolution.”

“I am excited to join the team at ABK, which has outstanding experience in the medical device industry. The talent at ABK, coupled with an innovative technology platform and pipeline, provide a strong foundation and solid prospects for our future growth and success,” said Mangano. “I especially look forward to working with the interventional radiology and oncology communities to develop and market novel technologies that will help patients and physicians, and want to thank the founders and the board of ABK for their support.” Dr. Bob Abraham, co-founder and former CEO, is a practicing interventional radiologist and will remain with the company as Chief Medical Officer. He will continue to play a key role in product development and the clinical evolution of ABK’s key technology platforms.

Mangano will continue to serve on the ABK board of directors.

ACOA Anounces $3M in Support to ABK for Easi-Vue Embolization Microspheres

Halifax, Nova Scotia, February 22nd 2018.

ABK Biomedical received support from the Atlantic Canada Opportunities Agency (ACOA) to commercialize its Easi-Vue embolization microspheres in-house. The successful commercialization of this innovation will lead to new business opportunities and more well-paying jobs as the microspheres are set to compete in global markets. The funding was announced in February 2018 at ABK’s new facility in Bayers Lake by Darrell Samson, MP for Sackville-Preston-Chezzetcook, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency. 

The contribution, being made through ACOA’s Atlantic Innovation Fund (AIF), is going towards the design and development of custom equipment as well as getting the regulatory approval needed for ABK Biomedical to scale-up its manufacturing process. It will support the manufacturing of devices in a clinical study, enabling regulatory approvals for sale of the device in the United States and globally. This AIF project will create six good quality jobs with the potential for more as demand for the product grows.

Quotes:
“Innovation isn’t just about finding solutions that make our lives better; it’s about improving everyone’s quality of life. That is why the Government of Canada is committed to supporting projects such as this one, which will have an international impact while enhancing Atlantic Canada’s ability to compete in the global marketplace.”
The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA 

“ABK Biomedical is one of the firms keeping Atlantic Canada’s life sciences community on the leading-edge. By keeping the manufacturing local, ABK will create new jobs and economic opportunities in the area, while setting itself up for international export. Today’s announcement will secure the commercialization of the microspheres to help cancer patients worldwide.”
Darrell Samson, Member of Parliament for Sackville-Preston-Chezzetcook

“This investment enhances our competitive presence by allowing us to accelerate plans to manufacture and export medical devices internationally directly from Halifax. ABK is now positioned to develop and sustain high quality jobs in the medical device sector in Atlantic Canada and our company and products will soon help improve the lives of patients with hyper vascular tumours globally.”
Dr. Bob Abraham, CEO, ABK Biomedical Inc.

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
E. 
info@abkbiomedical.com
T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA
E. 
info@abkbiomedical.com

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical may change the products mentioned at any time without notice. ABK Biomedical Inc. is a Pre-clinical stage company engaged in the active research and development of new medical devices. ABK Biomedical products are considered investigational only and are not FDA cleared for use..

(C) Copyright 2019 – All International Rights Reserved – ABK Biomedical Inc.